eCube Harnesses Machine Learning to Identify CNS Compounds and Predict Their Therapeutic Applications for Neuropsychiatric Disorders PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, announced today that it has launched eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform to support phenotypic drug discovery, which unlike traditional … [Read more…]

BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that its Chief Scientific Officer, Loïc Vincent, Ph.D., will present data from the Company’s oncogenic driver program targeting KRAS G12D, at this year’s American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, … [Read more…]

CareDx Receives Award for Introducing RemoTraC During Pandemic and Sponsoring the Honor the Gift Coalition for Successful Passage of the Immuno Bill BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that … [Read more…]

Top-Line Results from Part 1 of the Trial Expected in the Second Half of 2023 LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced enrollment of the first patient in the Phase 2 clinical trial of orally administered RASP modulator ADX‑629, an investigational new drug, for the treatment of atopic dermatitis. The multicenter, adaptive, … [Read more…]

SUZHOU, China–(BUSINESS WIRE)–Evopoint Biosciences Co., Ltd.(“Evopoint”), a biopharmaceutical company focused on discovering and developing innovative and transformative medicines, announced today a collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate Evopoint’s XNW5004, a selective EZH2 inhibitor, in combination with KEYTRUDA®(pembrolizumab), MSD’s anti-PD-1 therapy, in a Phase Ib/II study in Chinese patients with … [Read more…]

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced changes to its leadership team. Andrew Kirkpatrick, chief operating officer, is stepping down from the position of Chief Operating Officer, effective June 1, 2023, to pursue new opportunities. The Company has also created two new … [Read more…]

MINERAL WELLS, Texas–(BUSINESS WIRE)–#behavioralhealth–Electromedical Products International, Inc. (EPI), manufacturer of Alpha-Stim® technology, announced today the formation of its Scientific Advisory Board (SAB) comprising leading clinicians and researchers in neurology, psychiatry and neurostimulation. The SAB will work closely with EPI’s leadership team to provide scientific and clinical input into the company’s clinical trials in non-invasive brain … [Read more…]

IRVING, Texas–(BUSINESS WIRE)–Great Place To Work® and Fortune magazine have honored Vizient, Inc. as one of the 2023 Fortune 100 Best Companies to Work For®. This is Vizient’s second time being named to this prestigious list, this year coming in at No. 45. Earning a spot means that Vizient has surpassed rigorous benchmarks, establishing itself … [Read more…]

ADM invests in Brightseed to identify bioactives from microbe and plant interactions to develop the future of clinically validated synbiotic products CHICAGO & SAN FRANCISCO–(BUSINESS WIRE)–ADM, a global leader in nutrition that powers many of the world’s top food, beverage, and health and wellness brands, and Brightseed, the bioactives company and a World Economic Forum … [Read more…]

Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center now open for patient enrolment to pre|CISION™ lead programme, AVA6000 LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening on 5 April 2023 of the first two clinical investigator sites … [Read more…]